Herbert Irving Comprehensive Cancer Center
Flash Section
HICCC

Welcome to the Cancer Center's clinical trials online search tool. Clinical trials are studies designed to test the effectiveness of new treatments, including new drugs or new combinations of drugs.

Advanced Search Form


25 Results

Anus, Bones and Joints, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Ill-Defined Sites, Kaposis sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Melanoma, skin, Mesothelioma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAQ8124

Industry
Principal Investigator: Dr. Gulam Manji

Adult: Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Gulam Manji at 646-317-6041

Bones and Joints, Brain and Nervous System, Kidney, Liver

ID:AAAO2953

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: ADVL1315, A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# 123101) in Children with Recurrent or Refractory Solid Tumors

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Bones and Joints, Kidney, Liver, Soft Tissue

ID:AAAN9957

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: ADVL1314, A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas

This is a phase 1, multicenter, dose escalation study of Eribulin Mesylate, a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors, including lymphomas. . The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with refractory or recurrent solid tumors. Participants are given eribulin as an intravenous infusion on Day 1 and Day 8. Eribulin mesylate will be given directly into the vein through either a needle or small tubing inserted each treatment day or through a long-term catheter called a central line. This treatment pattern will be repeated every 21 days. This entire 21-day period is called a cycle. During the study, 13 blood samples will be collected to see how much of the eribulin mesylate is in each participants blood. This may require that a small intravenous tube (catheter or IV) be placed since some of the samples cannot be drawn from the site of drug administration. The blood samples (3 mL or about ˝ teaspoon each sample) will be obtained before the drug is given, and 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours after the drug is given on Day 1 of Cycle 1. A final sample will be collected 5 minutes after the drug is given on Day 8 of Cycle 1. A total of 39 mL (about 8 teaspoons total) will be taken for the pharmacokinetic tests in this study. This amount of blood is safe to draw even from small children. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Bones and Joints, Brain and Nervous System, Kidney, Liver, Lymphoid Leukemia, Soft Tissue

ID:AAAN6705

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Both: ADVL1411: A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

This is a phase I, multicenter, dose escalation study of BMN 673 in combination with temozolomide. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with relapsed or recurrent malignancies. BMN 673 is a PARP inhibitor that works by inhibiting cancer cell growth. In this study, BMN 673 will be administered in combination with temozolomide. The purpose of this study is to evaluate the toxicities and clinical activity of BMN 673 in children with relapsed or recurrent malignancies.BMN 673 will be given at the current standard dose once daily on days 1 through 6 of a cycle. Temozolomide is given once daily on days 2 through 6 of a cycle. A cycle is 28 days. Disease assessment will be completed before beginning treatment, before starting a new cycle, at the end of treatment. During every cycle, blood samples will be collected to determine how much BMN 673 is in the blood (pharmacokinetics). The blood tests will help us to better learn how to use this drug for children who may receive it in the future. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Anus, Bones and Joints, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mesothelioma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Bladder

ID:AAAP2403

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-6041

Breast - Female, Breast - Male, Colon, Kidney, Lung, Melanoma, skin, Mesothelioma, Pancreas, Soft Tissue

ID:AAAO1854

Industry
Principal Investigator: Dr. Kevin Kalinsky

Adult: A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors

This study is being done to determine how patients with advanced or refractory solid tumors (cancer that continues to grow in spite of receiving standard treatment) respond to increasing doses of an investigational drug, CB-839, to determine the dose of CB-839 that can be given without causing severe side effects and to look for early signs of clinical activity. CB-839 blocks the production of glutamate which is critical for tumor cell growth. Investigational means that has not been approved by the United States Food and Drug Administration (FDA) for use outside of research studies. This study will also determine the effect of the study drug by analyzing biomarkers. Biomarkers are substances in your body that can be used to detect a disease or to find out how the cancer is responding to treatment. In this study, biomarkers found in tumor tissue and blood will be collected and tested to see if the study drug causes changes in the way the cancer behaves. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Kevin Kalinsky at (646) 317-6041

Kidney, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Rectum, Stomach

ID:AAAP4008

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies

The purpose of this study is to identify the best dose of LAG525 alone or LAG525 with PDR001 that can be safely given to patients with cancer and to evaluate how well LAG525 or LAG525 and PDR001 together might work in treating patients with cancer. LAG525 acts by blocking a protein called LAG-3 and PDR001 acts by blocking a protein called PD-1. Blocking of these proteins may lead to an increased ability of the immune system to fight against tumor cells. This is the first time LAG525 by itself and LAG525 in combination with PDR001 will be studied in humans. There are two parts of this study, Phase I and Phase II. In Phase I, escalating doses of the drug or the combination of drugs are given to small groups of patients to identify the safest dose of the drug or combination of drugs to study further. In the Phase II part, the identified doses from the Phase I part of the study will be tested in patients with specific cancer types. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Naiyer Rizvi at 646-317-6344

Anus, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Male Genital, Other Urinary, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Bladder

ID:AAAO0006

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

This is a phase 1/1b research study for adults with a diagnosis of an advanced solid tumor for which thereare no standard therapies beyond those that may have already been received. This study involves aninvestigational (experimental) drug called MGCD516. Investigational means that MGCD516 is notapproved by the U.S. Food and Drug Administration (FDA). MGCD516 is designed to block specifictyrosine kinases, which are proteins that are thought to cause tumors to grow. MGCD516 is also designedto slow down the growth of new blood vessels that help tumors to grow and spread. Studies in animalswith tumors have shown that MGCD516 is able to shrink or slow down the growth of tumors. Thisclinical trial will be the first time that MGCD516 will be administered to humans.The main purposes of this study are to identify how much MGCD516 can safely be administered topatients, how much drug is absorbed after taking MGCD516 capsules orally and how quickly the drug iscleared from the blood stream. Other things that will be studied include the effects of MGCD516 on yourcancer and whether patients with very specific kinds of cancer should be included in future clinical trials. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at (646) 317-6041

Anus, Bones and Joints, Breast - Female, Breast - Male, Colon, Esophagus, Eye and Orbit, Ill-Defined Sites, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mesothelioma, Other Digestive Organ, Other Endocrine System, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAN9701

Industry
Principal Investigator: Dr. Emerson Lim

Adult: PRO 02/ML28897 MY PATHWAY STUDY: An Open-Label Phase IIA Study Evaluating Trastuzumab/ Pertuzumab, Erlotinib, Vermurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of these Agents

Four different treatment regimens will be evaluated simultaneously in groups of patients who have advanced solid tumors that has progressed following administration of standard of care treatment, or for whom no standard therapy exists, or for whom therapies that will convey clinical benefit are not available, and in whom a trial of targeted therapy is considered the best available treatment option.1. Erlotinib is a targeted drug that blocks the activity of epidermal growth factor receptor (EGFR), a protein found in increased amounts in certain cancers. EGFR, when overactive, leads to abnormal cell growth. By blocking the activity of EGFR, erlotinib works to help stop this abnormal growth.2. Trastuzumab and pertuzumab are drugs that target the HER2 receptor, a protein found in high quantities in HER2-positive cancers. Pertuzumab is believed to work in a way that is complementary to trastuzumab, as the two medicines target different regions on the HER2 receptor.3. Vemurafenib is a targeted drug that inhibits BRAF kinase, a protein found in certain cancers. BRAF kinase causes abnormal cell growth. By blocking the activity of the BRAF kinase, vemurafenib stops this abnormal growth. The presence of abnormal BRAF kinase in cancer cells can be detected by finding a mutation in the BRAF gene within the cancer.4. Vismodegib is a targeted drug that inhibits the hedgehog pathway in cancer cells. When overactive, the hedgehog pathway plays an important role in the cell’s ability to grow and multiply as a cancer cell. By blocking the hedgehog pathway, vismodegib can stop this abnormal growth. The hedgehog pathway is known to be overactive in cancers with mutations in the genes responsible for this pathway. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Emerson Lim at (212) 305- 0170

Brain and Nervous System, Kidney

ID:AAAP1101

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Both: ADVL1412, A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

This is a Phase 1/2 multicenter study of nivolumab as a single agent and in combination with ipilimumab. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with refractory or recurrent solid tumors. The purpose of this study is to evaluate toxicity and potential antitumor activity of nivolumab, a PD1 blocking mAb, in children with refractory or recurrent solid tumors and to test a combination regimen of nivolumab plus ipilimumab, which has shown activity in melanoma.Nivolumab of 3 mg/kg (Dose Level 1) will be administered as a 60-minute intravenous infusion every 14 days of a 28 day cycle. If Dose Level 1 is not tolerable, then the 3 mg/kg dose will be deescalated to 1 mg/kg and a similar cohort of patients will be evaluated for tolerability at this dose.Once the recommended phase 2 dose of nivolumab is determined, there will be a phase 2 cohort expansion for patients with neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma and non-Hodgkin lymphoma. Concurrently there will be an expansion to test a combination regimen of nivolumab plus ipilimumab, with the goal of identifying the maximum tolerated dose or recommended phase 2 dose of this combination. Ipilimumab will be administered as a 90-minute intravenous infusion.The combination of nivolumab and ipilimumab will be administered every 3 weeks for four cycles followed by nivolumab given every 2 weeks. Cycle length is 21 days for the first 4 cycles and 28 days for subsequent cycles which comprise two doses of nivolumab. Disease assessment will be completed before beginning treatment, before starting a new cycle, and at the end of study treatment. Blood samples will be collected to determine how much nivolumab and ipilimumab are in the blood during the study (pharmacokinetics). Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Anus, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Ill-Defined Sites, Kaposis sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Mesothelioma, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAP0559

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies

The purpose of this research study is to find the highest safe dose of the drug MGCD265 that can be given to participants with advanced cancer. The safety of this drug, and the effect that it has on the particpants disease and your body will also be studied. MGCD265 is a drug that works by blocking proteins that are important for cancer cells to grow. MGCD265 also prevents the growth of new blood vessels that help cancer tumors grow and spread. MGCD265 an investigational agent. This means that MGCD265 is not approved by the Food and Drug Administration (FDA). Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-6041

Bones and Joints, Brain and Nervous System, Kidney, Liver, Soft Tissue

ID:AAAN4703

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: ADVL1312, A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

This is a phase I, multicenter, dose escalation study of MK-1775 in combination with irinotecan. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with refractory or recurrent solid tumors. MK-1775 is an oral selective Wee1 kinase inhibitor that works by inhibiting cancer cell growth. In this study, MK-1775 will be administered in combination with irinotecan. The purpose of this study is to evaluate the toxicities and clinical activity of MK-1775 in children with nrefractory or recurrent solid tumors. Both drugs will be administered orally on days 1-5 of a 21-day cycle . Disease assessment will be completed before beginning treatment, before starting a new cycle, and at the end of study treatment. During every cycle, blood samples will be collected to determine how much MK-1775 is in the blood (pharmacokinetics). Once the recommended phase 2 dose of MK-1775 in combination with irinotecan is determined, there will be a phase 2 expansion for patients with refractory or recurrent neuroblastoma (Part B) and for patients with refractory or recurrent medulloblastoma/CNS PNET (Part C). Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Bones and Joints, Brain and Nervous System, Kidney, Liver, Soft Tissue

ID:AAAM3603

Industry
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab®-paclitaxel in pediatric patients with recurrent or refractory solid tumors.

This is a phase I, multicenter, dose finding study of nab-paclitaxel. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with recurrent or refractory solid tumors. Nab-paclitaxel is an human serum albumin bound nanoparticle formulation of paclitaxel that works by inhibiting cancer cell growth. The purpose of this study is to evaluate the toxicities and clinical activity of nab-paclitaxel in children with recurrent or refractory solid tumors. Nab-paclitaxel will be given based on the assigned dose level intravenously over approximately 30 minutes, on Days 1, 8, and 15 of a 28-day cycle. Disease assessment will be completed before beginning treatment, before starting a new cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study. During every cycle, blood samples will be collected to determine how much nab-paclitaxel is in the blood (pharmacokinetics). The blood tests will help us to better learn how to use this drug for children who may receive it in the future. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Prostate, Rectum, Bladder

ID:AAAQ6651

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

The purpose of this study is find out whether an investigational (experimental) drug called CPI-444 can be used, either on its own, or in combination with another investigational drug called atezolizumab (also known as MPDL3280A) on you and the specific type of cancer you have.We want to find out the best dose of CPI-444, both on its own and in combination with atezolizumab and what effects, good and/or bad, either CPI-444 on its own or in combination with atezolizumab has on you and your cancer. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Naiyer Rizvi at (646) 317-3141

Colon, Esophagus, Kidney, Lung, Melanoma, skin, Prostate, Soft Tissue, Bladder

ID:AAAQ6730

Industry
Principal Investigator: Dr. Catherine Shu

Adult: A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab and Demcizumab plus Pembrolizumab, Pemetrexed and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab (Arm A of the study). Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the growth of cancer stem cells, in addition to the remaining cancer cells, and it may also prevent the growth of new blood vessels that tumors need to grow and spread. Demcizumab, used in this study, is experimental. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Catherine Shu at 646-317-3141

Kidney

ID:AAAQ6970

Industry
Principal Investigator: Dr. Edward Gelmann

Adult: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

The purpose of this study is to compare the effectiveness of tivozanib in renal cell cancer compared to an approved drug “sorafenib” which works in a similar way to tivozanib. Tivozanib and sorafenib are both called “study medication”. This study will also see whether tivozanib is safe and tolerable for patients with advanced renal cell cancer.This study will look at the effects of tivozanib on subjects with refractory advanced renal cell cancer. Subjects who agree to participate in this study and are qualified to be in this study will receive either tivozanib or sorafenib. The decision about which study medication you receive will be based on random assignment (like tossing a coin). This study is “open label”, which means that both you and the study doctor will know which drug you are receiving. About half of subjects will receive tivozanib and about half of subjects will receive sorafenib. The study doctor or study staff will tell you whether you are receiving tivozanib or sorafenib.You will be one of about 322 subjects who take part in this study at about 190 study centers worldwide. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Edward Gelmann at 212 305-5098

Colon, Kidney, Lung, Melanoma, skin, Soft Tissue

ID:AAAQ7663

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination with Immune Therapeutic Agents in Adult Subjects with Advanced Solid Tumors

The primary objective is to assess safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD; in the absence of exceeding the MTD) for the combination of MEDI0562 and MEDI4736 or tremelimumab in subjects with advanced solid tumors. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Naiyer Rizvi at 646-317-3141

Colon, Kidney, Lung, Melanoma, skin, Soft Tissue

ID:AAAQ4411

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects with Selected Advanced Solid Tumors

This study is being carried out to evaluate MEDI0562 in treating advanced solid tumors. MEDI0562 is an experimental drug. “Experimental” means the drug has not been approved by any Authority that regulates new medicines, including the United States of America (US) Food and Drug Administration (FDA). MEDI0562, the experimental drug used in this study, is a monoclonal antibody that binds to and activates the human OX40 protein (also known as CD134). OX40 is involved in activating the immune system, so it is possible that binding of MEDI0562 to OX40 may help activate your immune system. Cancers can be recognized by the immune system, and under some circumstances the immune system may control or even eliminate tumors. The normal function of OX40 in the immune system is to improve immune responses by activating specific immune cells. Binding of MEDI0562 with OX40 may activate your immune system to eliminate cancer cells. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Naiyer Rizvi at 646-317-3141

Bones and Joints, Brain and Nervous System, Kidney, Liver, Soft Tissue

ID:AAAQ7819

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: ADVL1621: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Bones and Joints, Brain and Nervous System, Kidney, Liver, Soft Tissue

ID:AAAQ4204

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XP01 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Anus, Bones and Joints, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Ill-Defined Sites, Kaposis sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mesothelioma, Mycosis Fungoides, Non-Hodgkins Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Bladder

ID:AAAQ4758

Industry
Principal Investigator: Dr. Emerson Lim

Adult: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY 1251152 in patients with advanced cancer

The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Emerson Lim at 646-317-6041

Bones and Joints, Brain and Nervous System, Kidney, Liver, Soft Tissue

ID:AAAQ5801

Cooperative Group
Principal Investigator: Dr. Julia Glade Bender

Pediatrics: ADVL1416, A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Breast - Female, Cervix, Colon, Kidney, Liver, Lung, Melanoma, skin, Other Female Genital, Other Male Genital, Ovary, Pancreas, Prostate, Bladder

ID:AAAQ8183

Industry
Principal Investigator: Dr. Richard Carvajal

Adult: A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Richard Carvajal at 646-317-3141

Kidney, Lung, Soft Tissue

ID:AAAQ4064

Cooperative Group
Principal Investigator: Dr. Alice Lee

Adult: ADVL1522: A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call 646-317-0540

Cervix, Kidney, Liver, Lung, Melanoma, skin, Other Female Genital, Small Intestine, Bladder

ID:AAAQ8228

Industry
Principal Investigator: Dr. Naiyer Rizvi

Adult: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CARCINOMAS

The purpose of this research study is to learn about the effects of the study drugs, PF-04518600 and PF-05082566, and to:- Find out what side effects occur when PF-04518600 is given alone or in combination with PF-05082566, and how long they last,- Find the optimal dose of PF-04518600 alone or in combination with PF-05082566, for treating adult research subjects/participants with cancer.- Measure how much of PF-04518600 or PF-05082566 is in your blood after you take the study drug(s),- Find out if your body makes antibodies against PF-04518600 or PF-05082566,- Find out if PF-04518600 given alone or in combination with PF-05082566 changes how your immune system responds to cancer,- Find out if PF-04518600 given alone or in combination with PF-05082566 will be effective in shrinking tumors. Please click here to view more information in ClinicalTrials.gov.
For more information about this trial, please call Dr. Naiyer Rizvi at 212-305-3997

bottom